The **Evolution** and **Clinical Significance** of **NSAIDs** and the **Future** Directions

Authored by Koddus Ali

Non-steroidal anti-inflammatory drugs (NSAIDs) have become a foundation in the management of pain and inflammation due to their widespread efficacy, accessibility, and the extensive research supporting their use across various clinical conditions. The historical evolution of NSAIDs, beginning with the introduction of aspirin over a century ago, laid the groundwork for their current status in pain management. Aspirin's analgesic and anti-inflammatory properties were quickly recognised, leading to the development of other NSAIDs such as ibuprofen and naproxen, which have since gained popularity for their effectiveness in treating mild to moderate pain and inflammation (Cavkaytar et al., 2015; Poddubnyy, 2013).

The mechanism of action of NSAIDs primarily involves the inhibition of cyclooxygenase (COX) enzymes, which play a crucial role in the conversion of arachidonic acid to prostaglandins, compounds that mediate inflammation and pain (Sánchez-Borges et al., 2002; Whittle, 2003). The discovery of two distinct COX isoforms, COX-1 and COX-2, has further refined the therapeutic

applications of NSAIDs. COX-1 is involved in the maintenance of gastric mucosa and renal function, while COX-2 is primarily expressed during inflammatory responses (Sánchez-Borges et al., 2002; Sung et al., 2000). This understanding has led to the development of selective COX-2 inhibitors, which aim to provide anti-inflammatory benefits while minimising gastrointestinal side effects associated with non-selective NSAIDs (Akarca, 2005).

Clinical studies have consistently demonstrated the efficacy of NSAIDs in various conditions, including arthritis, musculoskeletal disorders, and postoperative pain (Poddubnyy, 2013; Rossignol et al., 2008). For instance, a study on axial spondyloarthritis showed that NSAIDs significantly reduced pain and stiffness in patients, highlighting their role as a first-line treatment option (Poddubnyy, 2013). Additionally, the use of topical NSAIDs has gained traction, particularly for localised pain management, as they provide analgesic effects with minimal systemic absorption, thus reducing the risk of systemic side effects (Bhat, 2023).

The safety profile of NSAIDs has been a topic of extensive research, particularly concerning gastrointestinal complications. While NSAIDs are effective, they are also associated with risks such as peptic ulcers and gastrointestinal bleeding, especially in long-term users (Akarca, 2005; Sugano et al., 2012). The introduction of proton pump inhibitors (PPIs) as a preventive measure against

NSAID-induced gastrointestinal complications has been a significant advancement in the management of patients requiring long-term NSAID therapy (Sung et al., 2000). Research has shown that the combination of NSAIDs with PPIs can effectively reduce the incidence of gastrointestinal adverse events, allowing for safer long-term use (Sugano et al., 2012).

In addition to gastrointestinal safety, the potential for hypersensitivity reactions to NSAIDs has been documented, with varying degrees of severity ranging from mild urticaria to anaphylaxis (Çerçi, 2023; Kowalski et al., 2011). Understanding the mechanisms behind these hypersensitivity reactions has led to improved classification and management strategies, allowing clinicians to better navigate the complexities of NSAID use in sensitive populations (Çerçi, 2023; Kowalski et al., 2011). For example, selective COX-2 inhibitors like celecoxib have been explored for their tolerability in patients with a history of NSAID hypersensitivity, showing promise in minimising adverse reactions while providing effective pain relief (Li & Laidlaw, 2019).

The accessibility of NSAIDs, both prescription and over-the-counter, has also contributed to their prominence in pain management. Their availability allows patients to self-manage mild to moderate pain effectively, which is particularly beneficial in primary care settings (Cavkaytar et al., 2015; Bruyndonckx et al.,

2018). However, the ease of access necessitates careful patient education regarding the appropriate use of NSAIDs, potential side effects, and the importance of consulting healthcare providers for prolonged use (Bruyndonckx et al., 2018).

Research continues to evolve around NSAIDs, with ongoing studies aimed at optimising their use and minimising adverse effects. For instance, the exploration of novel formulations and delivery methods, such as transdermal patches and injectable forms, aims to enhance the therapeutic efficacy of NSAIDs while reducing systemic exposure (Bhat, 2023). Furthermore, the integration of NSAIDs into multimodal pain management strategies, particularly in surgical and chronic pain settings, underlines their versatility and importance in contemporary pain management protocols (Rossignol et al., 2008).

Mechanism of Action

The role of COX enzymes in the therapeutic effects of NSAIDs is multifaceted and critical to understanding how these medications alleviate pain and inflammation, as well as their potential chemopreventive properties in various diseases, including cancer. COX enzymes, primarily COX-1 and COX-2, are pivotal in the conversion of arachidonic acid into prostaglandins, which are lipid compounds that mediate inflammation, pain, and fever. The inhibition of these enzymes by NSAIDs leads to a decrease in

prostaglandin synthesis, thereby exerting anti-inflammatory and analgesic effects (Baek et al., 2021; Ayub & Islam, 2015).

COX-1 is constitutively expressed in many tissues and is responsible for producing prostaglandins that protect the gastric mucosa and maintain renal blood flow, while COX-2 is an inducible enzyme that is upregulated during inflammation and is associated with pain and inflammatory responses (Crofford, 2000). The selective inhibition of COX-2 has been shown to provide effective pain relief with a reduced risk of gastrointestinal side effects compared to non-selective NSAIDs that inhibit both COX-1 and COX-2 (Rodríguez et al., 2008; Rao & Reddy, 2004). This selectivity is particularly important in clinical settings where long-term NSAID use is necessary, as it minimises adverse effects while maximising therapeutic benefits (Rao & Reddy, 2004).

Research indicates that the therapeutic effects of NSAIDs extend beyond mere COX inhibition. For instance, certain NSAIDs have been found to exert COX-independent effects, such as modulating γ-secretase activity, which is implicated in Alzheimer's disease pathology through the regulation of amyloid-beta peptide production (Eriksen et al., 2003; Weggen et al., 2003). This suggests that the therapeutic potential of NSAIDs may encompass a broader range of mechanisms, including direct interactions with cellular

pathways involved in inflammation and cell proliferation (Mizushima, 2010).

In the context of cancer, the inhibition of COX-2 has been linked to reduced tumorigenesis and improved outcomes in various malignancies. Studies have demonstrated that NSAIDs can decrease the incidence of colorectal cancer by inhibiting COX-2-derived prostaglandin E2 signaling, which is known to promote tumour growth and angiogenesis (Yong & DuBois, 2006; Zeidler et al., 2000). Furthermore, genetic and pharmacological studies have shown that the antitumor effects of NSAIDs are mediated, at least in part, through COX inhibition, although COX-independent mechanisms also play a role in their chemo preventive actions (Martínez et al., 2003; Narayanan et al., 2004).

The dual functionality of NSAIDs, involving both COX-dependent and COX-independent pathways, highlights the complexity of their action. For example, while traditional NSAIDs like aspirin and ibuprofen primarily exert their effects through COX inhibition, other compounds may activate specific genes or pathways that contribute to their anti-inflammatory and antitumor effects (Baek et al., 2002; Turchanowa et al., 2001). This multifactorial approach to understanding NSAID action is crucial for developing new therapeutic strategies that maximise efficacy while minimising side effects.

Furthermore, the pharmacokinetics of NSAIDs, including their selectivity for COX-1 versus COX-2, significantly influences their clinical application. For instance, COX-2 selective inhibitors, known as coxibs, have been developed to provide anti-inflammatory effects with a lower risk of gastrointestinal complications, making them preferable for patients requiring long-term treatment (Rodríguez et al., 2008; Rao & Reddy, 2004). However, the potential cardiovascular risks associated with selective COX-2 inhibition have raised concerns, necessitating careful patient selection and monitoring (Rodríguez et al., 2008).

In addition to their analgesic and anti-inflammatory properties, NSAIDs have been investigated for their role in modulating immune responses. The inhibition of COX-2 can lead to alterations in cytokine production and immune cell function, which may contribute to their therapeutic effects in inflammatory diseases and cancer (Miranda et al., 2019; Zeidler et al., 2000). This immune modulation is particularly relevant in the context of chronic inflammatory conditions, where persistent inflammation is a key driver of disease progression.

The understanding of COX enzymes and their role in NSAID action continues to evolve, with ongoing research exploring novel compounds that may offer enhanced therapeutic profiles. For instance, the identification of new COX isoforms and variants, such

as COX-3, has opened avenues for targeted therapies that could provide pain relief with fewer side effects (Chandrasekharan et al., 2002). Additionally, the exploration of NSAID combinations with other therapeutic agents may enhance their efficacy and broaden their applications in clinical practice (F et al., 2020).

Clinical Uses Across Specialties

NSAIDs widespread use can be attributed to their ability to alleviate symptoms of musculoskeletal disorders, inflammatory diseases, and acute pain episodes, making them key in both primary and specialised medical care. Conditions such as osteoarthritis, rheumatoid arthritis, and acute injuries are particularly prevalent among NSAID prescriptions, as these drugs provide significant symptomatic relief through their anti-inflammatory properties (Al-Saeed, 2011; Bhattarai et al., 2021; Wongrakpanich et al., 2018).

NSAIDs reduce the production of prostaglandins by inhibiting these enzymes, which in turn lowers inflammation and pain perception. This pharmacological action is particularly beneficial in chronic conditions such as osteoarthritis and rheumatoid arthritis, where inflammation is a significant contributor to pain and disability (Vanderstraeten et al., 2016; Naseem et al., 2021). Furthermore, the analgesic properties of NSAIDs make them a preferred choice for acute pain management, including

postoperative pain and dental pain (Shukla, 2024; Wongrakpanich et al., 2018).

In addition to musculoskeletal disorders, NSAIDs are frequently prescribed for various other conditions. For instance, they are commonly used to manage pain associated with cancer, where inflammatory symptoms can significantly impact the quality of life (Setiawan et al., 2017). The use of NSAIDs in cancer patients is particularly relevant as they can help alleviate pain and swelling that often accompany tumour growth and treatment-related side effects. Furthermore, NSAIDs are also utilised in the management of headaches, menstrual pain, and other acute pain conditions, further underscoring their versatility as analgesics (Al-Saeed, 2011; Wongrakpanich et al., 2018).

Despite their efficacy, the prescription of NSAIDs is not without risks. Adverse effects associated with NSAID use, such as gastrointestinal bleeding, renal impairment, and cardiovascular events, necessitate careful consideration by healthcare providers (Wongrakpanich et al., 2018; Roubille et al., 2013; Narsinghani & Sharma, 2014). For instance, patients with pre-existing conditions such as chronic kidney disease (CKD) or cardiovascular disease may be at an increased risk for complications when using NSAIDs, leading to a more cautious approach in prescribing these medications (Keohane et al., 2017). Consequently, healthcare

providers often assess the risk-benefit ratio before initiating NSAID therapy, particularly in vulnerable populations such as the elderly (Wongrakpanich et al., 2018; Narsinghani & Sharma, 2014).

The prevalence of NSAID prescriptions is also influenced by clinical guidelines and treatment protocols that recommend their use as first-line therapy for pain and inflammation (Vanderstraeten et al., 2016; Naseem et al., 2021). In many cases, NSAIDs are recommended after the failure of non-pharmacological interventions or other analgesics, such as acetaminophen (Vanderstraeten et al., 2016). This stepwise approach to pain management reflects the recognition of NSAIDs as effective agents for controlling pain and inflammation while also acknowledging the potential for adverse effects.

Furthermore, the prescribing patterns of NSAIDs can vary based on the clinical setting. In outpatient settings, NSAIDs are often prescribed for chronic conditions, while in emergency departments, they may be used for acute pain management (Neupane et al., 2022). This variability highlights the adaptability of NSAIDs in addressing a wide range of clinical scenarios, reinforcing their status as a mainstay in pain management.

Adverse Effects and Safety Concerns

The major health risks associated with NSAID use include gastrointestinal complications, cardiovascular events, and renal

impairment, with certain populations being particularly vulnerable to these adverse effects. Understanding these risks is crucial for both healthcare providers and patients to ensure safe and effective use of these medications.

Gastrointestinal complications are among the most well-documented risks associated with NSAID use. These complications can range from mild dyspepsia to severe conditions such as peptic ulcers and gastrointestinal bleeding. The risk of these adverse effects is dose-dependent and is particularly pronounced in older adults and those with a history of gastrointestinal disorders (McGettigan & Henry, 2013). A meta-analysis indicated that NSAIDs, especially non-selective ones, significantly increase the risk of serious gastrointestinal events (Ungprasert et al., 2015). Furthermore, the concurrent use of NSAIDs with anticoagulants has been shown to heighten the risk of major bleeding (Penner et al., 2022). This is particularly concerning for patients with pre-existing gastrointestinal issues or those taking multiple medications, as polypharmacy can exacerbate the risk of adverse drug reactions (Moore et al., 2015).

Cardiovascular risks associated with NSAID use are also significant. Studies have shown that NSAIDs can elevate blood pressure and increase the risk of acute myocardial infarction (AMI) (Bally et al., 2017; , Shau et al., 2012). The risk is particularly pronounced with

higher doses and prolonged use, leading to a growing concern regarding the safety of NSAIDs in patients with existing cardiovascular conditions (McGettigan & Henry, 2013). For instance, a study highlighted that the risk of AMI is influenced by the timing and dosage of NSAID exposure, suggesting that even short-term use can pose risks for susceptible individuals (Bally et al., 2017). Additionally, certain demographic groups, such as older adults and those with pre-existing cardiovascular diseases, are at an increased risk for these adverse outcomes (Lin et al., 2021).

Renal impairment is another critical concern linked to NSAID use. NSAIDs can lead to acute kidney injury (AKI), particularly in populations with pre-existing renal conditions such as chronic kidney disease (CKD) (Patel et al., 2012). The mechanisms by which NSAIDs induce renal damage include inhibition of prostaglandin synthesis, which is essential for maintaining renal blood flow, especially in states of dehydration or compromised renal function (Chiasson et al., 2019). Research has indicated that the prevalence of NSAID use in patients with CKD is alarmingly high, despite guidelines recommending against their use in this population (Gnjidic et al., 2014). Additionally, the risk of nephrotoxicity is compounded in older adults, who often have multiple comorbidities and may be taking other nephrotoxic medications (Lin et al., 2021).

Certain populations are particularly vulnerable to the adverse effects of NSAIDs. Older adults are at increased risk due to age-related physiological changes, polypharmacy, and the higher prevalence of comorbid conditions (Gnjidic et al., 2014). Also, individuals with pre-existing gastrointestinal, cardiovascular, or renal conditions are more likely to experience severe complications from NSAID use (McGettigan & Henry, 2013). For instance, a study found that older adults using NSAIDs had a significantly higher incidence of AKI compared to younger populations (Lin et al., 2021). Furthermore, patients with a history of gastrointestinal bleeding or ulcers should be closely monitored when prescribed NSAIDs, as they are at a heightened risk for recurrence of these complications (Moore et al., 2015).

The knowledge and perceptions of patients regarding the risks associated with NSAID use also play a crucial role in their safety. Research has shown that many patients, particularly those with lower educational levels, may not fully understand the potential risks of NSAIDs, which can lead to misuse (Phueanpinit et al., 2016). This lack of awareness can result in patients failing to disclose relevant medical histories that could influence the safety of NSAID prescriptions. Therefore, enhancing patient education regarding the risks associated with NSAIDs is essential for improving safety outcomes (Phueanpinit et al., 2016).

Comparative Efficacy and Novel Developments in NSAIDs

The comparison between traditional NSAIDs and COX-2 inhibitors has been a focal point of research, particularly concerning their efficacy and safety profiles. Traditional NSAIDs, such as ibuprofen and naproxen, are non-selective inhibitors that affect both COX-1 and COX-2 enzymes, while COX-2 inhibitors, like celecoxib and etoricoxib, are designed to selectively inhibit the COX-2 enzyme, which is primarily involved in inflammation and pain signalling. This selectivity has significant implications for both therapeutic efficacy and adverse effects, particularly gastrointestinal and cardiovascular risks.

Efficacy-wise, studies have shown that COX-2 inhibitors can provide pain relief comparable to traditional NSAIDs in conditions such as osteoarthritis and rheumatoid arthritis. For instance, Kivitz et al. demonstrated that celecoxib was as effective as naproxen in alleviating pain associated with osteoarthritis of the hip, while also highlighting its superior gastrointestinal safety profile (Kivitz et al., 2001). This finding is supported by other studies indicating that COX-2 inhibitors maintain similar analgesic effects while reducing the risk of gastrointestinal complications (Baraf, 2007). Furthermore, a systematic review found that COX-2 inhibitors were associated with a lower incidence of upper gastrointestinal ulcers and complications compared to traditional NSAIDs, reinforcing

their role as a safer alternative for long-term pain management (Bakhriansyah et al., 2017).

In terms of safety, traditional NSAIDs are associated with a higher risk of gastrointestinal adverse events, including ulcers and bleeding, due to their inhibition of COX-1, which plays a protective role in the gastric mucosa (Levy & Imundo, 2010; Süleyman et al., 2008). This is particularly concerning in populations at risk, such as the elderly or those with pre-existing gastrointestinal conditions. Bakhriansyah et al. reported that selective COX-2 inhibitors, especially when used in conjunction with PPIs, significantly reduce the risk of gastrointestinal ulcers compared to traditional NSAIDs (Bakhriansyah et al., 2017). Furthermore, observational studies have shown that patients using COX-2 inhibitors had lower rates of upper gastrointestinal complications compared to those on non-selective NSAIDs, even when controlling for disease severity (Mamdani, 2002; Mamdani et al., 2004).

However, the safety profile of COX-2 inhibitors is not without concerns. Research has indicated that selective COX-2 inhibitors may increase the risk of cardiovascular events due to their mechanism of action. Solomon et al. highlighted that while COX-2 inhibitors reduce prostacyclin production an important vasodilator they do not affect thromboxane A2 levels, which promote platelet aggregation and vasoconstriction, potentially leading to increased

cardiovascular risks (Solomon et al., 2005; Solomon et al., 2004). This dual effect raises questions about the long-term safety of COX-2 inhibitors, particularly in patients with existing cardiovascular conditions.

The cardiovascular safety of COX-2 inhibitors has been a subject of extensive debate, particularly following the withdrawal of rofecoxib from the market due to safety concerns. Kearney et al. conducted a meta-analysis that suggested both traditional NSAIDs and COX-2 inhibitors could increase the risk of atherothrombosis, although the exact mechanisms and relative risks remain unclear (Kearney et al., 2006). The cardiovascular risks associated with COX-2 inhibitors have led to recommendations for careful patient selection and monitoring, particularly in those with pre-existing cardiovascular disease (Williams et al., 2006).

While both traditional NSAIDs and selective COX-2 inhibitors are effective for pain management, their safety profiles differ significantly. COX-2 inhibitors offer a lower risk of gastrointestinal complications, making them preferable for long-term use in patients at risk for gastrointestinal issues. However, the potential for increased cardiovascular events necessitates a cautious approach, particularly in vulnerable populations. The choice between these classes of medications should be guided by a

thorough assessment of the patient's individual risk factors and treatment goals.

Conclusion

NSAIDs have undergone significant evolution since their inception, transitioning from the discovery of aspirin to the development of advanced selective COX-2 inhibitors. Their broad therapeutic utility across conditions such as arthritis, postoperative pain, and localised inflammation has solidified their role as indispensable agents in contemporary medicine. However, their widespread use is tempered by notable safety concerns, including gastrointestinal, cardiovascular, and renal risks, necessitating a balanced approach to their prescription and use. Advances in understanding the molecular mechanisms of NSAIDs, such as COX-dependent and COX-independent pathways, have broadened their potential applications, including emerging roles in cancer prevention and immune modulation.

Future directions in NSAID research focus on enhancing their therapeutic efficacy while minimising adverse effects. Innovations in drug formulations, such as transdermal patches and injectable options, alongside the integration of NSAIDs into multimodal pain management strategies, highlight their evolving clinical relevance. Additionally, personalised medicine approaches, including patient-specific risk assessments and the use of protective co-

therapies like PPI's, hold promise for improving the safety and effectiveness of NSAID therapy.

While NSAIDs remain a crucial in pain and inflammation management, continued research and vigilance are required to optimise their clinical application, expand their therapeutic potential, and mitigate their risks. This balance will ensure that NSAIDs remain both a reliable and safe choice for managing diverse medical conditions in the future.

References

Akarca, U. (2005). Gastrointestinal effects of selective and non-selective non-steroidal anti- inflammatory drugs. Current Pharmaceutical Design, 11(14), 1779-1793. https://doi.org/10.2174/1381612053764904

Al-Saeed, A. (2011). Gastrointestinal and cardiovascular risk of nonsteroidalanti-inflammatory drugs. Oman Medical Journal, 26(6), 385-391. https://doi.org/10.5001/omj.2011.101

Ayub, M. and Islam, A. (2015). Prevalence of nsaids (non steroidal inflammatory drugs) as a chemopreventive agent in different types of cancer: retrospective detail studies. Oalib, 02(08), 1-11. https://doi.org/10.4236/oalib.1101830

Baek, S., Hwang, S., Park, T., Kwon, Y., Cho, M., & Park, D. (2021). Evaluation of selective cox-2 inhibition and in silico study of kuwanon derivatives isolated from morus alba. International Journal of Molecular Sciences, 22(7), 3659. https://doi.org/10.3390/ijms22073659

Baek, S., Wilson, L., Lee, C., & Eling, T. (2002). Dual function of nonsteroidal anti-inflammatory drugs (nsaids): inhibition of cyclooxygenase and induction of nsaid-activated gene. Journal of Pharmacology and Experimental Therapeutics, 301(3), 1126-1131. https://doi.org/10.1124/jpet.301.3.1126

Bakhriansyah, M., Souverein, P., Boer, A., & Klungel, O. (2017). Gastrointestinal toxicity among patients taking selective cox-2 inhibitors or conventional nsaids, alone or combined with proton pump inhibitors: a case–control study. Pharmacoepidemiology and Drug Safety, 26(10), 1141-1148. https://doi.org/10.1002/pds.4183

Bally, M., Beauchamp, M., Abrahamowicz, M., Nadeau, L., & Brophy, J. (2017). Risk of acute myocardial infarction with real-world nsaids depends on dose and timing of exposure. Pharmacoepidemiology and Drug Safety, 27(1), 69-77. https://doi.org/10.1002/pds.4358

Baraf, H. (2007). Efficacy of the newest cox-2 selective inhibitors in rheumatic disease. Current Pharmaceutical Design, 13(22), 2228-2236. https://doi.org/10.2174/138161207781368819

Bhat, C. (2023). Topical nonsteroidal anti-inflammatory drugs. Canadian Medical Association Journal, 195(36), E1231-E1231. https://doi.org/10.1503/cmaj.230578

Bhattarai, A., Acharya, A., & Khanal, K. (2021). Non-steroidal anti-inflammatory drugs in orthopedic outpatient cases in a tertiary care teaching hospital: a descriptive cross-sectional study. Journal of Nepal Medical Association, 59(243), 1116-1119. https://doi.org/10.31729/jnma.6767

Bruyndonckx, R., Verhoeven, V., Anthierens, S., Cornelis, K., Ackaert, K., Gielen, B., … & Coenen, S. (2018). The implementation of academic detailing and its effectiveness on appropriate prescribing of pain relief medication: a real-world cluster randomized trial in belgian general practices. Implementation Science, 13(1). https://doi.org/10.1186/s13012-017-0703-8

Cavkaytar, Ö., Yılmaz, E., Karaatmaca, B., Büyüktiryaki, B., Saçkesen, C., Şekerel, B., … & Soyer, Ö. (2015). Different phenotypes of non-steroidal anti-inflammatory drug hypersensitivity during childhood. International Archives of Allergy and Immunology, 167(3), 211-221. https://doi.org/10.1159/000438992

Çerçi, P. (2023). Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in adults. Allergologia Et Immunopathologia, 51(5), 84-92. https://doi.org/10.15586/aei.v51i5.946

Chandrasekharan, N., Dai, H., Roos, K., Evanson, N., Tomsik, J., Elton, T., … & Simmons, D. (2002). Cox-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences, 99(21), 13926-13931. https://doi.org/10.1073/pnas.162468699

Chiasson, J., Fominaya, C., Gebregziabher, M., & Taber, D. (2019). Long-term assessment of nsaid prescriptions and potential nephrotoxicity risk in adult kidney

transplant recipients. Transplantation, 103(12), 2675-2681. https://doi.org/10.1097/tp.0000000000002689

Crofford, L. (2000). Clinical experience with specific cox-2 inhibitors in arthritis. Current Pharmaceutical Design, 6(17), 1725-1736. https://doi.org/10.2174/1381612003398753

Eriksen, J., Sagi, S., Smith, T., Weggen, S., Das, P., McLendon, D., … & Golde, T. (2003). Nsaids and enantiomers of flurbiprofen target γ-secretase and lower aβ42 in vivo. Journal of Clinical Investigation, 112(3), 440-449. https://doi.org/10.1172/jci18162

F, M., Noriega, V., Sierralta, F., Sotomayor-Zárate, R., & Carlo, P. (2020). Nsaids and opioids antinociception in a thermal murine phasic pain. GSC Advanced Research and Reviews, 2(3), 064-070. https://doi.org/10.30574/gscarr.2020.2.3.0022

Gnjidic, D., Blyth, F., Couteur, D., Cumming, R., McLachlan, A., Handelsman, D., … & Naganathan, V. (2014). Nonsteroidal anti-inflammatory drugs (nsaids) in older people: prescribing patterns according to pain prevalence and adherence to clinical guidelines. Pain, 155(9), 1814-1820. https://doi.org/10.1016/j.pain.2014.06.009

Kearney, P., Baigent, C., Godwin, J., Halls, H., Emberson, J., & Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? meta-analysis of randomised trials. BMJ, 332(7553), 1302-1308. https://doi.org/10.1136/bmj.332.7553.1302

Keohane, D., Dennehy, T., Keohane, K., & Shanahan, E. (2017). Reducing inappropriate non-steroidal anti-inflammatory prescription in primary care patients with chronic kidney disease. International Journal of Health Care Quality Assurance, 30(7), 638-644. https://doi.org/10.1108/ijhcqa-09-2016-0145

Kivitz, A., Moskowitz, R., Woods, E., Rc, H., Verburg, K., Lefkowith, J., … & Geis, G. (2001). Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. Journal of International Medical Research, 29(6), 467-479. https://doi.org/10.1177/147323000102900602

Kowalski, M., Makowska, J., Blanca, M., Bavbek, S., Bochenek, G., Bousquet, J., … & Brockow, K. (2011). Hypersensitivity to nonsteroidal anti-inflammatory drugs (nsaids) - classification, diagnosis and management: review of the eaaci/enda# and ga2len/hanna*. Allergy, 66(7), 818-829. https://doi.org/10.1111/j.1398-9995.2011.02557.x

Levy, D. and Imundo, L. (2010). Nonsteroidal anti-inflammatory drugs: a survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data. Pediatric Rheumatology, 8(1). https://doi.org/10.1186/1546-0096-8-7

Li, L. and Laidlaw, T. (2019). Cross-reactivity and tolerability of celecoxib in adult patients with nsaid hypersensitivity. The Journal of Allergy and Clinical Immunology in Practice, 7(8), 2891-2893.e4. https://doi.org/10.1016/j.jaip.2019.04.042

Lin, S., Phillips, T., Culliford, D., Edwards, C., Holroyd, C., Ibrahim, K., … & Fraser, S. (2021). Characterising risk of non-steroidal anti-inflammatory drug-related acute kidney injury: a retrospective cohort study. BJGP Open, 6(1), BJGPO.2021.0208. https://doi.org/10.3399/bjgpo.2021.0208

Mamdani, M. (2002). Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ, 325(7365), 624-624. https://doi.org/10.1136/bmj.325.7365.624

Mamdani, M., Juurlink, D., Kopp, A., Naglie, G., Austin, P., & Laupacis, A. (2004). Gastrointestinal bleeding after the introduction of cox 2 inhibitors: ecological study. BMJ, 328(7453), 1415-1416. https://doi.org/10.1136/bmj.38068.716262.f7

Martínez, M., O'Brien, T., Fultz, K., Babbar, N., Yerushalmi, H., Qu, N., … & Gerner, E. (2003). Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proceedings of the National Academy of Sciences, 100(13), 7859-7864. https://doi.org/10.1073/pnas.1332465100

McGettigan, P. and Henry, D. (2013). Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. Plos Medicine, 10(2), e1001388. https://doi.org/10.1371/journal.pmed.1001388

Miranda, H., Noriega, V., Sierralta, F., Poblete, P., Aranda, N., & Prieto, J. (2019). Nitric oxide and opioids involvement in isobolographic nsaids antinociception. Drug Research, 69(12), 688-694. https://doi.org/10.1055/a-0983-1402

Mizushima, T. (2010). Molecular mechanism for various pharmacological activities of nsaids. Pharmaceuticals, 3(5), 1614-1636. https://doi.org/10.3390/ph3051614

Moore, N., Pollack, C., & Butkerait, P. (2015). Adverse drug reactions and drug–drug interactions with over-the-counter nsaids. Therapeutics and Clinical Risk Management, 1061. https://doi.org/10.2147/tcrm.s79135

Narayanan, B., Narayanan, N., Pittman, B., & Reddy, B. (2004). Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clinical Cancer Research, 10(22), 7727-7737. https://doi.org/10.1158/1078-0432.ccr-04-0732

Narsinghani, T. and Sharma, R. (2014). Lead optimization on conventional non-steroidal anti-inflammatory drugs: an approach to reduce gastrointestinal toxicity. Chemical Biology & Drug Design, 84(1), 1-23. https://doi.org/10.1111/cbdd.12292

Naseem, S., Zahoor, A., Choudhary, Z., & Sultana, T. (2021). A study on prescribing patterns in patients with rheumatoid arthritis.. The Professional Medical Journal, 28(7), 1044-1048. https://doi.org/10.29309/tpmj/2021.28.07.6137

Neupane, G., Rai, M., & Rokaya, P. (2022). Patterns of prescription and adverse drug reaction profile of non- steroidal anti-inflammatory drugs at orthopedic out-patients department. Nepal Medical College Journal, 24(2), 170-175. https://doi.org/10.3126/nmcj.v24i2.46045

Patel, K., Diamantidis, C., Zhan, M., Hsu, V., Walker, L., Gardner, J., … & Fink, J. (2012). Influence of creatinine versus glomerular filtration rate on non-steroidal anti-inflammatory drug prescriptions in chronic kidney disease. American Journal of Nephrology, 36(1), 19-26. https://doi.org/10.1159/000339439

Penner, L., Gavan, S., Ashcroft, D., Peek, N., & Elliott, R. (2022). Does coprescribing nonsteroidal anti-inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?. British Journal of Clinical Pharmacology, 88(11), 4789-4811. https://doi.org/10.1111/bcp.15371

Phueanpinit, P., Pongwecharak, J., Krska, J., & Jarernsiripornkul, N. (2016). Knowledge and perceptions of the risks of non-steroidal anti-inflammatory drugs among orthopaedic patients in thailand. International Journal of Clinical Pharmacy, 38(5), 1269-1276. https://doi.org/10.1007/s11096-016-0363-9

Poddubnyy, D. (2013). Axial spondyloarthritis: is there a treatment of choice?. Therapeutic Advances in Musculoskeletal Disease, 5(1), 45-54. https://doi.org/10.1177/1759720x12468658

Rao, C. and Reddy, B. (2004). Nsaids and chemoprevention. Current Cancer Drug Targets, 4(1), 29-42. https://doi.org/10.2174/1568009043481632

Rodríguez, L., Tacconelli, S., & Patrignani, P. (2008). Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. Journal of the American College of Cardiology, 52(20), 1628-1636. https://doi.org/10.1016/j.jacc.2008.08.041

Rossignol, M., Abouelfath, A., Lassalle, R., Merlière, Y., Droz, C., Bégaud, B., … & Fourrier-Réglat, A. (2008). The cadeus study: burden of nonsteroidal anti-inflammatory drug (nsaid) utilization for musculoskeletal disorders in blue collar workers. British Journal of Clinical Pharmacology, 67(1), 118-124. https://doi.org/10.1111/j.1365-2125.2008.03318.x

Roubille, C., Martel-Pelletier, J., Davy, J., Haraoui, B., & Pelletier, J. (2013). Cardiovascular adverse effects of anti-inflammatory drugs. Anti-Inflammatory & Anti-

Allergy Agents in Medicinal Chemistry, 12(1), 55-67. https://doi.org/10.2174/1871523011312010008

Sánchez-Borges, M., Capriles-Hulett, A., & Caballero-Fonseca, F. (2002). Nsaid-induced urticaria and angioedema. American Journal of Clinical Dermatology, 3(9), 599-607. https://doi.org/10.2165/00128071-200203090-00002

Setiawan, A., Yin, L., Auer, G., Czene, K., Smedby, K., & Pawitan, Y. (2017). Patterns of acute inflammatory symptoms prior to cancer diagnosis. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-00133-8

Shau, W., Chen, H., Chen, S., Chou, H., Chang, C., Kuo, C., … & Lai, M. (2012). Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (nsaids): a case-crossover study of taiwan's national health insurance claims database and review of current evidence. BMC Cardiovascular Disorders, 12(1). https://doi.org/10.1186/1471-2261-12-4

Shukla, K. (2024). Prospective evaluation of dental practitioners' knowledge, attitude, and practice toward adult dental pain management: a cross-sectional multicenter study. Cureus. https://doi.org/10.7759/cureus.55388

Solomon, D., Schneeweiß, S., Glynn, R., Kiyota, Y., Levin, R., Mogun, H., … & Avorn, J. (2004). Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation, 109(17), 2068-2073. https://doi.org/10.1161/01.cir.0000127578.21885.3e

Solomon, S., McMurray, J., Pfeffer, M., Wittes, J., Fowler, R., Finn, P., … & Bertagnolli, M. (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine, 352(11), 1071-1080. https://doi.org/10.1056/nejmoa050405

Sugano, K., Kinoshita, Y., Miwa, H., & Takeuchi, T. (2012). Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in japanese patients. Alimentary Pharmacology & Therapeutics, 36(2), 115-125. https://doi.org/10.1111/j.1365-2036.2012.05133.x

Süleyman, H., Çadırcı, E., Albayrak, A., & Halıcı, Z. (2008). Nimesulide is a selective cox-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Current Medicinal Chemistry, 15(3), 278-283. https://doi.org/10.2174/092986708783497247

Sung, J., Russell, R., Yeomans, N., Chan, F., Chen, S., Fock, K., … & Brooks, P. (2000). Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. Journal of Gastroenterology and Hepatology, 15(s3). https://doi.org/10.1046/j.1440-1746.2000.02267.x

Turchanowa, L., Dauletbaev, N., Milovic, V., & Stein, J. (2001). Nonsteroidal anti-inflammatory drugs stimulate spermidine/spermine acetyltransferase and deplete polyamine content in colon cancer cells. European Journal of Clinical Investigation, 31(10), 887-893. https://doi.org/10.1046/j.1365-2362.2001.00901.x

Ungprasert, P., Cheungpasitporn, W., Crowson, C., & Matteson, E. (2015). Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. European Journal of Internal Medicine, 26(4), 285-291. https://doi.org/10.1016/j.ejim.2015.03.008

Vanderstraeten, G., Lejeune, T., Piessevaux, H., Bacquer, D., Walker, C., & Beleyr, B. (2016). Gastrointestinal risk assessment in patients requiring non-steroidal anti-inflammatory drugs for osteoarthritis: the girano study. Journal of Rehabilitation Medicine, 48(8), 705-710. https://doi.org/10.2340/16501977-2119

Weggen, S., Eriksen, J., Sagi, S., Pietrzik, C., Ozols, V., Fauq, A., … & Koo, E. (2003). Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity. Journal of Biological Chemistry, 278(34), 31831-31837. https://doi.org/10.1074/jbc.m303592200

Whittle, B. (2003). Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundamental and Clinical Pharmacology, 17(3), 301-313. https://doi.org/10.1046/j.1472-8206.2003.00135.x

Williams, D., Singh, M., & Hind, C. (2006). The effect of the withdrawal of rofecoxib on prescribing patterns of cox-2 inhibitors in scotland. British Journal of Clinical Pharmacology, 62(3), 366-368. https://doi.org/10.1111/j.1365-2125.2006.02691.x

Wongrakpanich, S., Wongrakpanich, A., Melhado, K., & Rangaswami, J. (2018). A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging and Disease, 9(1), 143. https://doi.org/10.14336/ad.2017.0306

Yong, I. and DuBois, R. (2006). Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin e2 signaling: recent advances in basic biology. Current Colorectal Cancer Reports, 2(2), 60-65. https://doi.org/10.1007/s11888-006-0003-1

Zeidler, R., Csánady, M., Gires, O., Lang, S., Schmitt, B., & Wollenberg, B. (2000). Tumor cell-derived prostaglandin e2 inhibits monocyte function by interfering with ccr5 and mac-1. The Faseb Journal, 14(5), 661-668. https://doi.org/10.1096/fasebj.14.5.661